Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026
Parasitological efficacy of seasonal malaria chemoprevention in Nampula, northern Mozambique.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bonnington Craig, Sitoe Mercia, Pulido Tarquino Ivan A, Enosse Sonia M, Sararat Chayanin, Suwannasin Kanokorn, Proux Stephane, Koesukwiwat Urairat, Tarning Joel, Imwong Mallika, Theiss-Nyland Katherine, Nosten François Henri, White Nicholas John
Аннотация
BACKGROUND: Deployment of seasonal malaria chemoprevention (SMC) for young children using monthly sulphadoxine-pyrimethamine-amodiaquine (SPAQ) has recently been extended to Central and East Africa.
METHODS: A pilot pharmacometric assessment was nested within a larger deployment of SMC in a high malaria transmission area in northern Mozambique. SPAQ was given to 460 healthy children in two large villages. Simultaneous filter-paper blood spot malaria quantitative PCRs, blood slide microscopy and antimalarial drug measurements were taken before, then 7 and 28 d after first SPAQ administration.
RESULTS: After SPAQ, parasitaemia prevalence decreased from 68% to 41%. Among children followed successfully for 28 d, malaria parasitaemia prevalence declined from 71% to 44%. Preventive efficacy was 97% for Plasmodium ovale and 42% for Plasmodium falciparum. Reinfections (N=50 with sufficient DNA for genotyping) and recrudescences (N=3) often grew through high concentrations of desethylamodiaquine, yet all 250 P. falciparum isolates genotyped were Pfcrt 76K, a molecular marker of 4-aminoquinoline susceptibility. One-third (21/64) of microscopy-detectable breakthrough P. falciparum infections had patent gametocytaemia. There was a clear chemoprevention exposure-response relationship evident for desethylamodiaquine, but not for sulphadoxine or pyrimethamine.
CONCLUSIONS: In Nampula, northern Mozambique, amodiaquine had low parasitological efficacy and sulphadoxine and pyrimethamine did not contribute significantly to chemoprevention.
METHODS: A pilot pharmacometric assessment was nested within a larger deployment of SMC in a high malaria transmission area in northern Mozambique. SPAQ was given to 460 healthy children in two large villages. Simultaneous filter-paper blood spot malaria quantitative PCRs, blood slide microscopy and antimalarial drug measurements were taken before, then 7 and 28 d after first SPAQ administration.
RESULTS: After SPAQ, parasitaemia prevalence decreased from 68% to 41%. Among children followed successfully for 28 d, malaria parasitaemia prevalence declined from 71% to 44%. Preventive efficacy was 97% for Plasmodium ovale and 42% for Plasmodium falciparum. Reinfections (N=50 with sufficient DNA for genotyping) and recrudescences (N=3) often grew through high concentrations of desethylamodiaquine, yet all 250 P. falciparum isolates genotyped were Pfcrt 76K, a molecular marker of 4-aminoquinoline susceptibility. One-third (21/64) of microscopy-detectable breakthrough P. falciparum infections had patent gametocytaemia. There was a clear chemoprevention exposure-response relationship evident for desethylamodiaquine, but not for sulphadoxine or pyrimethamine.
CONCLUSIONS: In Nampula, northern Mozambique, amodiaquine had low parasitological efficacy and sulphadoxine and pyrimethamine did not contribute significantly to chemoprevention.